drugset / Trial / NCT01827046

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

NCT01827046 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

A phase III, randomized, case-controlled, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage (ICH).

Timeline

Start
2013-12-30
Primary completion
2018-09
Completion
2018-09

Outcome

Missed primary endpoint

paper The mITT primary adjusted efficacy analysis estimated that 45% of patients in the MISTIE group and 41% patients in the standard medical care group had achieved an mRS score of 0-3 at 365 days (adjusted risk difference 4% [95% CI -4 to 12]; p=0·33). PMID 30739747 ↗

paper INTERPRETATION: For moderate to large intracerebral haemorrhage, MISTIE did not improve the proportion of patients who achieved a good response 365 days after intracerebral haemorrhage. PMID 30739747 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 1 mg Other